future diagnostics - wim smit 24032011
DESCRIPTION
TRANSCRIPT
Mission
Future Diagnostics intends to become the best developer for third parties of high‐quality and innovative diagnostic tests, today, and in the future, seen in the eyes of our customers and our employees.
VisionFuture Diagnostics intends to become the market leader in test development for third parties
We want to become the independent partner of the top 25 IVD companies for their test development
We would like to achieve this position by translating new technologies and novel ‘Intellectual Properties’ to the development of innovative tests with the shortest possible development time at the lowest possible costs
Facts
Founded May 01st, 1997
Privately owned
Current number of employees is 65
Current number of projects is 35 out of a maximum of 40
Highly qualified staff
ISO 9001/2000 and ISO 13485 compliant
FDA inspections in 2004 and 2008
Objective
The development of diagnostic tests and technologies for third parties
We are able to carry out development projects on almost any platform
Antibody Screening
Feasibility
Optimization
Verification
Technical Validation
Clinical Validation
Pilot Production
Support in 510(k) filing and CE registration
Facilities
Total 3500 m2
( Lab: 2000 m2 )
Operational February 2011
Bone Fertility Cancer
Bioactive PTHCalcitoninCip and CapDPDIntact‐PTHPTHPTHrp1,25‐OH Vitamin D25‐OH Vitamin DVitamin D BP
AldosteroneAndrostendione11‐Desoxy‐cortisolDHEADHEA‐SDHTEstradiolEstriolFree testosteronehCGLH17‐OH ProgesteroneSHBGTestosterone
β‐2MEGFEGF receptorE2 receptorFree PSAIGF‐1IGFBP3P53Progesterone receptorPSA
> 120 developed assays
Cardiovascular Endocrine Infectious disease
AngiotensinANPBNPCatecholaminesCK‐MBD‐DimerFactor VIIIFibrin‐monomerFibrinogenGalectin‐3HS‐CRPMyoglobinNT Pro‐BNPProtein‐CPro‐reninRenincTroponint‐PA‐PAI‐1uPA‐PAI‐1VasopressinvWF
ACTHAnti‐TgAnti‐TPOC‐peptideCorticosteronCortisolCortisonHbA1cFecal Occult BloodFree T3GastrinGHBPhGHIL‐2 receptorIL‐6InsulinMelatoninNewborn screeningThyroglobulin
Anti‐HBcAnti‐HBsCMV IgG+IgMEBVGonorrheaHBcTHBsAgHBsAg confirmativeHCVHIV AbHIV Ag+AbHIV‐1,2,”O”LymeRubella IgG+IgMSyphilisToxoplasmosis IgG+IgMTuberculosis
IntraOperative Autoimmune
STAT‐ACTHSTAT‐C‐peptideSTAT‐InsulinSTAT‐Intact PTH
Anti‐Cardiolipin IgG+ IgMAnti‐GADAnti‐IA2Anti‐InsulinAnti‐SMSMultiplex auto antibodies
Anemia Drugs of Abuse Others
EPOFerritinFolateVitamin B12
AtrazineDESSalbutamol
cGMPCGRPCow Milk ProgesteroneFPAMAP2OpsinRhodopsinS100Tyrosine Kinase
Our Customers
Experience on many platformsImmuno analyzers
Chemistry analyzers
Other
Partnerships
Intellectual Property Vitamin D
Intellectual Property HbA1c
Experience in Technologies
Chemiluminescence
Bioluminescence
Fluorescence
Enzyme Based Immuno Assay
Colorimetric Assays
Turbidimetric Assays
DNA Assays
Point of Care
How we make our lab yours?
Monthly Fee Royalties on sales
Balanced out = Shared Risk
Wie is mijn klant?
Wie is mijn klant?
R&D of Business Development
Wat voor businessmodel?
Fee of een royalty project?
Wat voor businessmodel?
Fee of een royalty project?
Wat is bepalend voor deze keus??
Hoe controleer ik mijn royalty inkomsten?
Hoe controleer ik mijn royalty inkomsten?
Hoe is FDx er zeker van dat het minimaal haar gemaakte kosten
terugverdiend?
Personeel
Hoe vang ik mijn piekbelasting op?
Liquiditeit
Hoe blijf ik aan mijn kortlopende verplichtingen voldoen?
• Less than 5% of the $3 trillion spent each year on the health care worldwide is for clinical laboratory services.
• Considering that nearly 70% of health care decisions are based on critical diagnostics information, biomedical testing represents a significant source of value in healthcare.
Trends in healthcare
Source: TriMark Publications
7/21/201128
Thank you for your attention